FDA said recently that United States current tetracycline shortage problem could not be resolved quickly, that is because production and raw material supply issues continue to occur.
Tetracycline is a broad-spectrum antibiotic used to treat a variety of infections. Since the middle of 2011, tetracycline in the United States has been in short supply on the market. At that time due to raw material procurement difficulties, making Watson (Watson) and Teva stopped the production of the drug, and that the two companies are United States market only 2 production of tetracycline, a company.
Now the above issues remain. LisaKubaska FDA staff said that in addition to Watson and Teva hit raw materials procurement issues, FDA has not found the right import channels.
She explained that, sometimes, when the United States market when there is a shortage of this product, FDA will look for alternative medicine by foreign manufacturers, but only if, these manufacturers have accepted the FDA inspection group to check.